Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas

• A. Arnold ^[1] ; S. Daum ^[1] ; M. von Winterfeld ^[2] ; E. Berg ^[1] ; M. Hummel ^[1] ; B. Rau ^[1] ; U. Stein ^[1] ; C. Treese ^[1]
  1. [1] Charité-Universitätsmedizin Berlin, Alemania
  2. [2] University Hospital Heidelberg, Alemania
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 22, Nº. 12 (December), 2020, págs. 2357-2363
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction The tight junction molecule Claudin 18.2 is selectively expressed in healthy and malignant gastric epithelial tissue and is a promising therapy target for high Claudin 18.2 expressing adenocarcinomas of the esophagogastric junction and stomach (AEG/S).

    Methods This study analyzed the prevalence, characteristics and prognostic impact of Claudin 18.2 expression in primary tumor, lymph node and distant metastasis in a large Caucasian AGE/S cohort with 414 patients.

    Results Claudin 18.2 was highly expressed in 17.1% of primary tumors, 26.7% of lymph node metastasis and 16.7% of distant metastasis. High Claudin 18.2 expression in lymph node metastasis and primary tumors correlated significantly (p < 0.001). High expression of Claudin 18.2 was neither associated with histomorphogical subtype, or tumor state, nor with overall survival.

    Conclusion In Caucasian AEG/S patients, 17.1% appeared to be eligible for an anti-Claudin 18.2 therapy. Claudin 18.2 expression itself has no impact on prognosis and is not related to any tumor subtype.